
What is claimed is:

1. Use of anti-cancer agent represented by Formula (I):



(I),

or a pharmaceutically acceptable salt thereof in the manufacture of medicament for the treatment of lymphoma in a subject in combination with at least one anti-cancer therapy selected from the group consisting of rituximab, cyclophosphamide, doxorubicin or a pharmaceutically acceptable salt thereof, vincristine or a pharmaceutically acceptable salt thereof, and prednisolone.

2. The use of claim 1, wherein the lymphoma is a Hodgkin lymphoma.

3. The use of claim 1, wherein the lymphoma is a non-Hodgkin lymphoma

4. The use of claim 1 or 3, wherein the lymphoma is a B-cell lymphoma.

5. The use of any one of claims 1, 3, and 4, wherein the lymphoma is selected from follicular lymphoma, DLBCL, MCL, Burkitt, and lymphoplasmacytic lymphoma.

6. The use of any one of claims 1 and 3 to 5, wherein the lymphoma is selected from DLBCL, MCL, and Burkitt lymphoma.

7. The use of any one of claims 1 and 3 to 6, wherein the lymphoma is selected from DLBCL and MCL.

8. The use of any one of claims 1 and 3 to 6, wherein the lymphoma is DLBCL.

9. The use of claim 1 or 3, wherein the lymphoma is a T-cell lymphoma.

10. The use of any one of claims 1, 3, and 9, wherein the lymphoma is a cutaneous T-cell lymphoma.

11. The use of any one of claims 1, 3, 9, and 10, wherein the lymphoma is selected from mycosis fungoide, PTCL, AITL, ALCL, EATL, and hepatosplenic gamma/delta T-cell lymphoma.

12. The use of any one of claims 1 to 11, wherein the anti-cancer agent and the anti-cancer therapy are administered simultaneously in the same or different formulations.

13. The use of any one of claims 1 to 12, wherein the anti-cancer agent and the anti-cancer therapy are administered sequentially.

14. The use of any one of claims 1 to 13, wherein the anti-cancer agent is the tris(hydroxymethyl)aminomethane salt of the compound of Formula (I).

15. The use of any one of claims 1 to 14, wherein the anti-cancer agent is the sodium salt of the compound of Formula (I).

16. The use of any one of claims 1 to 15, wherein the doxorubicin is doxorubicin hydrochloride.

17. The use of any one of claims 1 to 16, wherein the vincristine is vincristine sulfate.